Children with spinal muscular atrophy (SMA) showed motor function improvements after switching to onasemnogene abeparvovec following prior treatment with nusinersen or risdiplam in a real-world study.

DYNE-251 Granted FDA Breakthrough Therapy Designation for DMD

By Rose McNulty

August 13th 2025

DYNE-251 received FDA breakthrough therapy designation, showcasing its potential for patients with Duchenne muscular dystrophy (DMD).

The Impact of Health Benefit Design on Patients With Infertility

By Richard A. Brook, MS, MBA
Sanghyuk Seo, PharmD, MS

Ian A. Beren, BS
Tanyatorn Ghanjanasak, DO
Nathan L. Kleinman, PhD
Eric M. Rosenberg, MA
Emily S. Jungheim, MD

August 5th 2025

This retrospective analysis explored the impact of infertility health benefit design on the use of infertility medications and procedures and pregnancy outcomes.

ROS1-positive NSCLC is aggressive and rare, with approximately 3000 new diagnoses of advanced disease in the US each year. | Image credit: appledesign - stock.adobe.com

Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC

By Rose McNulty

July 31st 2025

Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).

KFF Survey: Most Consumers Find Prior Authorization Is a Major Problem

By Mary Caffrey

July 25th 2025

A new survey reveals widespread consumer frustration with prior authorization, highlighting the need for urgent reform in insurance coverage.

...

39 40 41 42 43

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions